Mr. Aaron Schachtis currently the Vice President of Global Research and Development / RegulatoryAffairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a roleof Global Brand Development Leader – Pain in Lilly Biomedicines. He was the globalleader for product development and commercialization activities for LY2951742 –Lilly’s novel CGRP neutralizing antibody – a new potential treatment forprevention of Migraine and Cluster Headache. In 2012, Schacht joined LillyBiomedicines as Senior Advisor – Strategy & Business Development for LillyBioMedicines.
His responsibilities included oversight of Therapeutic Strategydevelopment, R&D Portfolio Management, and Business Development for LillyBioMedicines – Lilly’s largest business unit. Past roles included serving asExecutive Director, Global External R&D, at Eli Lilly and Company, where hewas responsible for implementation of strategies which aim to leverage novelapproaches to external partnerships to augment Lilly’s access to pharmaceuticalinnovation as well as Executive Director of LRL (Lilly Research Labs) Strategy,Portfolio Management and Project Management where he was responsible forstrategic planning, R&D portfolio and project management. Prior to theseroles, he was Director, Innovation Center in the eLilly organization where
hefocused on the exploration, incubation and implementation of new businessmodels and capabilities relevant to the strategic evolution of thepharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schachtwas co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MDcardiovascular drug discovery start-up. Mr. Schacht began his career at Lillyin 1990 as a medicinal chemist, and spent 5 years in the laboratory working todiscover pharmaceuticals to treat cardiovascular disorders. Schacht studiedOrganic chemistry at the University of Illinois, receiving his Bachelors ofScience degree in 1990.